Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
G-protein Coupled Receptors01:21

G-protein Coupled Receptors

G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Population pharmacokinetic-based dose adjustment of tiapride in patients with impaired renal function.

Annals of medicine·2026
Same author

Development of a Biphasic Modified-Release Ibuprofen Tablet Formulation: Single-Dose and Multiple-Dose Pharmacokinetics and Food-Effect Studies.

Clinical and translational science·2026
Same author

Signaling pathways of inflammation in CIA model of rheumatoid arthritis regulated by cannabichromene.

Journal of cannabis research·2026
Same author

Maternal and fetal outcomes of lipid-lowering drug use in pregnancy: A Czech nationwide study.

Journal of clinical lipidology·2026
Same author

Prevalence of anti-rituximab antibodies in autoimmune forms of glomerulonephritis and podocytopathies.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

Predictors of COVID-19 vaccination status: a nationwide linkage study in Czechia.

Journal of public health (Oxford, England)·2026

Related Experiment Video

Updated: May 16, 2026

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder
09:29

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Published on: January 9, 2015

MDR1 in paroxetine-induced sexual dysfunction.

Alexandra Zourková1, Ondřej Slanař, Jiří Jarkovský

  • 1Central European Institute of Technology, Masaryk University, Brno, Czech Republic. azourkova@fnbrno.cz

Journal of Sex & Marital Therapy
|November 17, 2012
PubMed
Summary

Genetic variations in the MDR1 gene are linked to paroxetine-induced sexual dysfunction, specifically difficulties with orgasm and lubrication, in women with eating disorders and anxiety. This finding may help predict and manage antidepressant side effects.

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

Related Experiment Videos

Last Updated: May 16, 2026

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder
09:29

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Published on: January 9, 2015

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

Area of Science:

  • Pharmacogenetics
  • Neuropsychopharmacology
  • Genetics

Background:

  • Selective serotonin reuptake inhibitors (SSRIs) like paroxetine are effective antidepressants but frequently cause sexual dysfunction.
  • Genetic factors, particularly polymorphisms in pharmacokinetic genes, may influence individual susceptibility to SSRI-induced sexual side effects.
  • The MDR1 gene (ABCB1) encodes P-glycoprotein, a transporter protein involved in drug metabolism and distribution.

Purpose of the Study:

  • To investigate the association between MDR1 gene polymorphisms and the occurrence of sexual dysfunction in women undergoing paroxetine treatment.
  • To explore the relationship between specific MDR1 polymorphisms and paroxetine-induced sexual dysfunction in patients with bulimia nervosa and anxiety disorders, as well as in healthy controls.

Main Methods:

  • Genotyping of the MDR1 G2677T/A polymorphism in 18 women with bulimia nervosa, 18 women with anxiety disorders, and 19 healthy control subjects.
  • Assessment of sexual function, including difficulties with orgasm and lubrication, in participants treated with paroxetine.
  • Statistical analysis to determine the correlation between MDR1 G2677T/A allele carriage and reported sexual dysfunction.

Main Results:

  • Carriers of the MDR1 G2677T/A gene polymorphism who were treated with paroxetine exhibited a statistically significant increase in difficulties with orgasm (p = .008).
  • These allele carriers also reported significantly higher rates of lubrication difficulties (p < .001) when treated with paroxetine.
  • The study identified a specific genetic marker associated with adverse sexual effects of paroxetine.

Conclusions:

  • MDR1 gene polymorphism, specifically the G2677T/A variant, is associated with an increased risk of paroxetine-induced sexual dysfunction, including difficulties with orgasm and lubrication.
  • These findings suggest that pharmacogenetic testing for MDR1 polymorphisms could aid in predicting and potentially preventing sexual side effects in patients treated with paroxetine.
  • Understanding the genetic basis of antidepressant-induced sexual dysfunction is crucial for optimizing psychopharmacological treatments and improving patient adherence.